<DOC>
	<DOCNO>NCT01223703</DOCNO>
	<brief_summary>The purpose study test hypothesis n-3 PUFAs improve leave ventricular systolic function patient stable chronic HF secondary nonischemic dilate cardiomyopathy ( NICM ) .</brief_summary>
	<brief_title>PUFAs Left Ventricular Function Heart Failure</brief_title>
	<detailed_description>The result GISSI-HF trial indicate patient chronic HF evidence-based medical therapy New York Heart Association ( NYHA ) functional class II-IV , long term treatment n-3 PUFAs 1 g daily reduces mortality hospitalization cardiovascular reason . Several potential mechanism may underlie beneficial effect n-3 polyunsaturated fatty acid ( PUFAs ) HF patient , include , limited , antiarrhythmic , hemodynamic action . The current investigation therefore design test hypothesis treatment n-3 PUFAs improve LV systolic function express EF patient stable chronic HF secondary nonischemic dilate cardiomyopathy ( NICM ) . Additionally , seek determine n-3 PUFAs also exert positive effect LV diastolic function assess echocardiography ; functional capacity assess cardiopulmonary stress test ( CPET ) ; New York Heart Association ( NYHA ) functional class .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>patient diagnosis non ischemic cardiomyopathy ( absence coronary artery disease , define absence stenosis &gt; 50 % , confirm angiography perform time diagnostic workup cardiomyopathy ) LV systolic dysfunction ( define EF &lt; 45 % ) Stable clinical condition minimal symptom least three month Evidencebased medical treatment maximum tolerate target dos least six month presence symptom evidence CAD diagnose noninvasive test ; peripheral arterial disease ; presence congenital primary valvular heart disease ; persistent atrial fibrillation ; inability perform bicycle ergometry noncardiac cause ; moderately severely reduced functional capacity ; NYHA functional class IV ; poor acoustic window limit ability ass echocardiographic measurement ; chronic lung disease ; advanced renal disease ( eGFR &lt; 30 mL/min/1.73 m2 ) ; advance liver disease ; disease limit life expectancy one year less ; contraindication study drug ; concomitant participation research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>n-3 PUFAs</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Dilated cardiomyopathy</keyword>
	<keyword>Ejection Fraction</keyword>
	<keyword>Exercise Capacity</keyword>
</DOC>